Intelligence · Clinical Development
Pipeline search results
Programs matching “acute-myeloid-leukemia” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 134 pipeline programs matching "acute-myeloid-leukemia" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Lintuzumab-Ac225
Actinium Pharmaceuticals
Acute Myeloid Leukemia
2 trials -
Liposome-encapsulated Daunorubicin-Cytarabine
Jazz Pharmaceuticals Ireland Limited
Acute Myeloid Leukemia
2 trials -
Liposome-encapsulated Daunorubicin-Cytarabine
Jazz Pharmaceuticals Ireland Limited
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
1 trial -
Luveltamab tazevibulin
SUTRO BIOPHARMA, INC.
Acute Myeloid Leukemia (AML)
1 trial -
MT-401
Marker Therapeutics
Acute Myeloid Leukemia
1 trial -
Midostaurin
Novartis Pharmaceuticals
Acute Myeloid Leukemia
1 trial -
Mitoxantrone liposome
The First People's Hospital of Lianyungang
Relapsed or Refractory Acute Myeloid Leukemia
1 trial -
Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
Olutasidenib
RIGEL PHARMACEUTICALS INC
Acute Myeloid Leukemia
1 trial -
Onvansertib
Cardiff Oncology
Acute Myeloid Leukemia
1 trial -
Oral Encochleated Amphotericin B (CAMB)
Matinas BioPharma Holdings
Acute Myeloid Leukemia
1 trial -
Oral arsenic trioxide
The University of Hong Kong
Acute Myeloid Leukemia
1 trial -
Pevonedistat
Takeda
Acute Myeloid Leukemia (AML)
2 trials -
Revumenib
Syndax Pharmaceuticals
Acute Myeloid Leukemia
2 trials -
S2023-056-01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
S2023-413-01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed/Refractory Acute Myeloid Leukemia
1 trial -
SHR2554/AZA + Overlapped TBF
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
SNDX-5613
Syndax Pharmaceuticals
Acute Myeloid Leukemia
1 trial -
Selinexor
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia (Relapsed/Refractory)
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Acute Myeloid Leukemia
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Acute Myeloid Leukemia (Relapsed/Refractory)
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Acute Myeloid Leukemia (AML)
3 trials -
Selinexor
Hospital Authority, Hong Kong
Acute Myeloid Leukemia, Adult
1 trial -
Tagraxofusp
Stemline Therapeutics B.V.
Acute Myeloid Leukemia
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.